SecBot SecBot

ELAN

Elanco Animal Health Inc
NYSE· Pharmaceutical Preparations· CIK 0001739104 Biotech & Drug Discovery
$26.41 −0.37 (−1.38%)
Nov 16 4:00 PM ET · prev $26.78
Market cap
$13.3B
Large cap
Consensus
Buy
86% Buy or better · 22 analysts
Median target
$31.00
+17% · range $25.00–35.00
1 year
+23.3%
from $21.42 · Nov 17
30 days
+12.4%
from $23.49
52-week range
$19.80–26.84
−2% from high · low May 19
Avg volume 20D
5.60M
shares / day
Short interest
32.92M
≈6.6% of shares · +5.8%
Days to cover
7.2
at average volume
Insider net
+$1.4M
5 buyers · 1 seller · since May 21
New fund stakes
1
Q3 2026 13F · 6 exits
Filing reports
19
analyzed by SecBot
SecBot read BULLISH 9 reports · 90 days
Balance 0 bearish · 4 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 4/9

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    5 insiders bought $1.5M at an average $23.31. 1 insider sold $100.0K. Price is 13% above their cost.

  • InstitutionsMIXED

    Q3 2026: 35 added (1 new), 34 trimmed or exited. Largest new: Qube Research & Technologies $53.0M.

  • AnalystsBULLISH

    19 of 22 rate it Buy or better. Median target $31.00 (+17%).

  • Short sellersSTEADY

    Short interest +5.8% to 32.92M shares. 7.2 days to cover, ≈6.6% of shares.

  • TrendUPTREND

    13% above its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
6
exits
$53.0M
in new stakes
FundMoveSharesValue
MARSHALL WACE, LLPDOUBLED10,021,771$224.4M
UBS Group AGTRIM5,232,713$117.2M
Artemis Investment Management LLPADD4,611,977$103.3M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPADD3,738,619$83.7M
Quantinno Capital Management LPADD3,267,641$73.2M
Qube Research & Technologies LtdNEW2,368,480$53.0M
BNP PARIBAS FINANCIAL MARKETSADD1,938,770$43.4M
HRT FINANCIAL LPDOUBLED1,406,151$31.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

22 analysts
Buy 86% rate it Buy or better
Strong Buy7Buy12Hold3Sell0Strong Sell0
12-month targets · 13 analysts

Price is inside the target range. Median implies +17%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 9, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Oct 29, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Oct 20, 2026Jefferies
DOWNGRADE
DOWNGRADEHold
Oct 16, 2026Goldman Sachs
INITIATE
INITIATEBuy
Aug 6, 2026UBS
MAINTAIN
MAINTAINBuy
Aug 6, 2026Keybanc
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$1.5M
bought · 5 insiders
$100.0K
sold · 1 insider
+13.3%
vs their $23.31 cost
DateInsiderTypeValue
Oct 30, 2026
Modi Rajeev A.
SEE REMARKS
Oct 30, 2026
AWARD$1.5K
Oct 30, 2026
VanHimbergen Robert M
EVP and CFO
Oct 30, 2026
AWARD$197.02
Oct 30, 2026
Simmons Jeffrey N
PRESIDENT, CEO AND DIRECTOR
Oct 30, 2026
AWARD$2.8K
Oct 16, 2026
Modi Rajeev A.
SEE REMARKS
Oct 16, 2026
AWARD$1.5K
Oct 16, 2026
VanHimbergen Robert M
EVP and CFO
Oct 16, 2026
AWARD$197.02
Oct 16, 2026
Simmons Jeffrey N
PRESIDENT, CEO AND DIRECTOR
Oct 16, 2026
AWARD$2.8K
Oct 15, 2026
Bettington Timothy J
SEE REMARKS
Oct 15, 2026
SELL$100.0K
Oct 2, 2026
Modi Rajeev A.
SEE REMARKS
Oct 2, 2026
AWARD$1.5K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

34 lobbying filings and 4 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
32,923,699
shares short
+5.8%
vs prior settlement
7.2
days to cover
≈6.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 SEC
Dodge & Cox filed an amended Schedule 13G disclosing a 12.3% passive stake in Elanco Animal Health as of September 30…
SC 13G/A · Impact 2/10
Nov 6, 2026 SEC
Elanco reported Q3 2026 revenue of $1.265B (+11% YoY, +9% organic constant currency) and adjusted EPS of $0.27…
8-K · Impact 6/10
Nov 6, 2026 Other
October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority
Latest U.S. Survey of 2,000+ Consumers Shows 93% of Pet Owners Maintained or Increased Pet Spending
Oct 30, 2026 Insider
Modi Rajeev A. was granted 64.047 shares
SEE REMARKS @ $23.06 ($1.5K)
Oct 30, 2026 Insider
VanHimbergen Robert M was granted 8.544 shares
EVP and CFO @ $23.06 ($197.02)
Oct 30, 2026 Insider
Simmons Jeffrey N was granted 122.59 shares
PRESIDENT, CEO AND DIRECTOR @ $23.06 ($2.8K)
Sep 30, 2026 Inst.
MARSHALL WACE, LLP · DOUBLED
10,021,771 shares ($224.4M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 6, 2026
Press release
October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority
Latest U.S. Survey of 2,000+ Consumers Shows 93% of Pet Owners Maintained or Increased Pet Spending in Past Three Months, Omnichannel Shift…
Nov 6, 2026
Earnings result
ELAN Q3 2026 Earnings: EPS $0.27 (+30.4% vs est)
Nov 3, 2026
Press release
Elanco to Participate in UBS Global Healthcare Conference
INDIANAPOLIS, Nov. 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the UBS Global Healthcare Conference on…
Oct 22, 2026
Press release
Elanco Animal Health Appoints Jamie Preston as Chief People Officer
Preston brings more than two decades of global HR leadership and workforce innovation experience; Dave Kinard to retire at year-end INDIANAPOLIS…
Sep 11, 2026
Earnings
Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement
INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2026 financial results…

SecBot reports

19 filings · 10 bullish · 0 bearish · 9 neutral
All ELAN filing & press-release reports (19)